DGAT1-1 Antibody

What is DGAT1 and why is it an important research target?

DGAT1 (diacylglycerol O-acyltransferase homolog 1) is a critical enzyme that catalyzes the terminal and rate-limiting step in triacylglycerol (TAG) synthesis by converting diacylglycerol (DAG) and acyl-CoA into TAG. This process is fundamental to lipid droplet formation and energy storage. DGAT1 has emerged as a significant research target due to its involvement in metabolic disorders, with studies showing that DGAT1 inhibition can decrease body weight, improve insulin sensitivity, and alleviate hepatic steatosis in diet-induced obese mouse models . Furthermore, DGAT1's role extends beyond metabolism to viral pathogenesis, as evidenced by its interaction with rotavirus proteins and subsequent degradation during infection . Its calculated molecular weight is 55 kDa, though it is typically observed between 50-57 kDa in experimental conditions .

What applications can DGAT1 antibodies be reliably used for?

DGAT1 antibodies have demonstrated utility across multiple experimental applications. Based on validated research, DGAT1 antibodies such as the 11561-1-AP can be effectively employed in Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA techniques . These applications allow researchers to detect DGAT1 protein expression, localization, and interactions in various experimental contexts. When selecting a DGAT1 antibody, researchers should verify its reactivity with their species of interest, as some antibodies show cross-reactivity with human, mouse, and rat DGAT1 proteins .

How do researchers differentiate between specific and non-specific DGAT1 antibody binding?

Differentiating specific from non-specific binding requires implementation of proper controls and validation procedures. Researchers should:

• Include a negative control using samples from DGAT1 knockout models or DGAT1-silenced cells

• Perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide

• Compare staining patterns with multiple DGAT1 antibodies targeting different epitopes

• Verify DGAT1 detection at the expected molecular weight range (50-57 kDa)

• Include positive controls from tissues known to express high levels of DGAT1 (e.g., small intestine, adipose tissue)

The pattern of DGAT1 detection should correlate with known biological distribution and be absent in knockout models.

What are the optimal conditions for using DGAT1 antibodies in Western blotting?

Optimal Western blot conditions for DGAT1 detection require careful consideration of several parameters:

• Sample preparation:

  • For microsomal DGAT1 preparation, homogenize tissues in buffer followed by differential centrifugation (first at 10,000 × g to remove debris, then at 100,000 × g to collect microsomal fractions)

  • Determine protein concentration using standard assays (e.g., Bio-Rad protein assay with BSA standard)

• Gel electrophoresis:

  • Use fresh samples when possible as DGAT1 is susceptible to degradation

  • Load appropriate positive controls from tissues with known DGAT1 expression

• Transfer and antibody incubation:

  • For antibodies like 11561-1-AP, use application-specific dilutions (documented dilution ranges from 1:50-1:500 depending on application)

  • Incubate in blocking buffer containing 5% non-fat milk or BSA

• Detection:

  • Verify detection in the 50-57 kDa range, which represents the observed molecular weight of DGAT1

  • Consider enhanced chemiluminescence detection systems for optimal sensitivity

How should researchers optimize immunohistochemistry protocols with DGAT1 antibodies?

Optimizing IHC protocols for DGAT1 detection involves:

• Antigen retrieval:

  • Primary recommendation: Use TE buffer at pH 9.0 for antigen retrieval

  • Alternative method: Citrate buffer at pH 6.0 may also be effective

• Antibody dilution:

  • For IHC applications with antibodies like 11561-1-AP, use dilutions ranging from 1:50-1:500

  • Always titrate antibodies in each testing system to determine optimal concentration

• Validation approaches:

  • Confirm positive staining in tissues known to express DGAT1

  • Human hepatocirrhosis tissue has been documented as a positive control for DGAT1 IHC

  • Include negative controls by omitting primary antibody or using DGAT1 knockout tissue

• Detection systems:

  • Use detection systems appropriate for the host species of the primary antibody

  • For rabbit-derived antibodies like 11561-1-AP, anti-rabbit secondary antibodies conjugated to HRP or fluorophores are suitable

What experimental considerations are critical when studying DGAT1 interactions with other proteins?

When investigating DGAT1 protein interactions:

• Co-immunoprecipitation approaches:

  • Optimize lysis buffer conditions to maintain protein-protein interactions

  • Use mild detergents (e.g., 1% Triton X-100) that preserve membrane protein associations

  • Consider antibody orientation (immunoprecipitating DGAT1 versus the interacting partner)

• Cross-validation techniques:

  • Confirm interactions using reciprocal co-immunoprecipitation

  • Employ proximity ligation assays or FRET to verify interactions in situ

  • For viral protein interactions (e.g., rotavirus NSP2), distinguish between different conformational forms of viral proteins

• Specific example from research:

  • Studies have shown that DGAT1 interacts with dispersed NSP2 (dNSP2) but not viroplasm-associated NSP2 (vNSP2) during rotavirus infection

  • Immunoprecipitation of DGAT1 followed by western blot with specific antibodies against different forms of NSP2 helped distinguish these interactions

How can researchers address inconsistent DGAT1 detection in Western blotting?

Inconsistent DGAT1 detection can be addressed through several interventions:

• Sample preparation refinement:

  • Ensure complete protein extraction by using appropriate detergents (e.g., 1% Triton X-100)

  • Include protease inhibitors in all buffers to prevent degradation

  • Prepare fresh samples when possible, as DGAT1 stability may decrease with freezing/thawing cycles

• Protocol optimization:

  • Adjust antibody concentration systematically (e.g., perform a dilution series)

  • Modify blocking conditions to reduce background (e.g., switch between milk and BSA)

  • Extend primary antibody incubation time (overnight at 4°C versus 1-2 hours at room temperature)

• Technical considerations:

  • Verify transfer efficiency by using reversible protein stains

  • Consider membrane type (PVDF versus nitrocellulose) as DGAT1 may bind preferentially to one

  • For microsomal preparations, ensure proper subcellular fractionation by confirming enrichment of ER markers

What controls are essential when using DGAT1 antibodies in studies involving gene silencing or knockout?

When employing DGAT1 gene silencing or knockout approaches:

• Validation controls:

  • Confirm gene silencing/knockout efficiency through both protein detection (Western blot) and mRNA quantification (qPCR)

  • Include wild-type controls processed in parallel

  • For siRNA approaches, incorporate irrelevant siRNA controls to account for transfection effects

• Functional controls:

  • Measure DGAT1 enzyme activity using established assays (e.g., fluorescent or radioligand-based assays)

  • Assess phenotypic changes known to occur with DGAT1 alterations (e.g., changes in lipid droplet formation)

• Rescue experiments:

  • Re-express DGAT1 in knockout systems to confirm phenotype reversibility

  • Research has demonstrated that expression of flag-tagged DGAT1 in DGAT1−/− MEFs can restore normal virus yield levels, confirming specific effects of DGAT1 loss

How can researchers differentiate between DGAT1 expression changes due to experimental conditions versus protein degradation?

Distinguishing genuine expression changes from degradation requires:

• Proteasomal degradation assessment:

  • Include proteasome inhibitors (e.g., MG132) in parallel samples

  • Studies have shown that adding MG132 prevents RV-induced DGAT1 degradation, confirming proteasome-dependent mechanisms

• Ubiquitination analysis:

  • Assess DGAT1 ubiquitination through co-immunoprecipitation with ubiquitin

  • Experiments using HA-tagged ubiquitin followed by immunoprecipitation have been effective in investigating DGAT1 ubiquitination

• Time-course experiments:

  • Monitor DGAT1 levels over multiple timepoints to distinguish gradual degradation from altered expression

  • Compare protein and mRNA levels simultaneously to identify post-transcriptional regulation

How can DGAT1 antibodies be utilized to study metabolic disorders?

DGAT1 antibodies provide powerful tools for investigating metabolic disorders:

• Expression analysis in disease models:

  • Compare DGAT1 expression levels between healthy and diseased tissues

  • Correlate DGAT1 expression with severity of metabolic phenotypes

  • Employ multiplexed immunofluorescence to assess DGAT1 co-localization with other metabolic enzymes

• Intervention studies:

  • Monitor changes in DGAT1 expression and localization following treatment with DGAT1 inhibitors like T-863

  • Assess DGAT1 expression in response to dietary interventions or exercise regimens

  • Examine modification of DGAT1 (phosphorylation, ubiquitination) in response to insulin or other hormones

• Tissue-specific analyses:

  • Compare DGAT1 expression and localization across metabolically active tissues

  • Research has demonstrated the value of preparing microsomal membranes from primary tissues (small intestine, white adipose tissue) for DGAT1 studies

What methodological approaches can be used to study DGAT1's role in viral pathogenesis?

To investigate DGAT1's role in viral pathogenesis:

• Protein-protein interaction studies:

  • Use co-immunoprecipitation followed by Western blotting to detect DGAT1 interactions with viral proteins

  • Employ proximity ligation assays to visualize interactions in situ

  • Research has demonstrated that DGAT1 interacts specifically with dispersed NSP2 (dNSP2) but not viroplasm-associated NSP2 (vNSP2) during rotavirus infection

• Degradation mechanism studies:

  • Monitor DGAT1 levels during viral infection time courses

  • Employ proteasome inhibitors to block degradation

  • Investigate ubiquitination patterns of DGAT1 during infection

• Functional analysis:

  • Compare viral yields between wild-type and DGAT1-deficient cells

  • Studies have shown that DGAT1 knockout in mouse embryo fibroblasts and human intestinal enteroids increases rotavirus yield approximately 4-5 fold

  • Perform rescue experiments by re-expressing DGAT1 in knockout systems to confirm specificity

How can researchers design experiments to clarify contradictions in DGAT1 research findings?

Addressing contradictory findings requires systematic experimental approaches:

• Reconciling conflicting viral replication results:

  • Earlier studies reported that silencing DGAT1 resulted in a 1.4-fold decrease in rotavirus yield, while more recent research found a 4-5 fold increase

  • Systematically evaluate differences in:

    • Cell types and culture conditions

    • Gene silencing efficiency (partial versus complete knockout)

    • Viral strains and infection parameters

    • Timing of measurements

• Methodological standardization:

  • Employ multiple complementary approaches to measure the same parameter

  • For example, combine protein- and cell-based assays to characterize DGAT1 inhibitor effects

  • Use standardized high-throughput assays like the fluorescent DGAT1 activity assay

• Comprehensive data collection:

  • Measure multiple parameters simultaneously (e.g., DGAT1 expression, enzymatic activity, lipid droplet formation)

  • Conduct time-course experiments to capture dynamic changes

  • Include genetic and pharmacological interventions in parallel to distinguish mechanism-based from compound-specific effects

How should researchers interpret variations in DGAT1 molecular weight across different experimental systems?

Variations in observed DGAT1 molecular weight require careful interpretation:

• Expected weight ranges:

  • Calculated molecular weight: 55 kDa (based on 488 amino acids)

  • Observed molecular weight range: 50-57 kDa

• Factors influencing molecular weight variation:

  • Post-translational modifications (glycosylation, phosphorylation)

  • Species differences (human vs. mouse vs. rat)

  • Sample preparation methods (denaturation conditions, buffer composition)

  • Gel percentage and running conditions

• Interpretative approach:

  • Always run appropriate molecular weight markers

  • Include positive controls from validated sources

  • Consider western blotting with multiple antibodies targeting different DGAT1 epitopes

  • Verify identity through mass spectrometry if novel bands are observed

What statistical approaches are most appropriate for quantifying DGAT1 expression changes?

When quantifying DGAT1 expression changes:

• Data normalization strategies:

  • Normalize DGAT1 signals to appropriate housekeeping proteins

  • For microsomal preparations, consider normalizing to ER-resident proteins rather than cytosolic markers

  • Account for loading variations using total protein normalization methods

• Statistical analysis methods:

  • For comparing two conditions: paired t-tests for matched samples

  • For multiple experimental conditions: ANOVA followed by appropriate post-hoc tests

  • For non-normally distributed data: non-parametric alternatives (Mann-Whitney, Kruskal-Wallis)

• Reporting standards:

  • Present data as fold-change relative to control conditions

  • Include measures of variability (standard deviation, standard error)

  • Report exact p-values rather than significance thresholds

  • Present both representative blots and quantification from multiple independent experiments

How can researchers integrate DGAT1 expression data with functional lipid metabolism parameters?

Integrating DGAT1 expression with functional parameters requires:

• Correlation analyses:

  • Plot DGAT1 expression levels against functional readouts (e.g., triglyceride levels, insulin sensitivity)

  • Calculate correlation coefficients (Pearson's r for linear relationships, Spearman's ρ for non-linear associations)

  • Consider multivariate approaches to account for confounding variables

• Mechanistic validation:

  • Test causality through intervention studies (e.g., DGAT1 inhibitors, gene silencing)

  • Examine dose-response relationships between DGAT1 expression/activity and metabolic parameters

  • Research has demonstrated that DGAT1 inhibition with compounds like T-863 can improve metabolic parameters in a dose-dependent manner

• System-level integration:

  • Combine DGAT1 expression data with expression of other lipid metabolism enzymes

  • Consider pathway analysis approaches to identify coordinated regulation

  • Incorporate transcriptomic, proteomic, and lipidomic data for comprehensive understanding